Croatia power consumption - Dec 01, 2023
Serbia power consumption - Dec 01, 2023
Bulgaria power consumption - Dec 01, 2023
Croatia’s share indices extend gains thanks to Podravka, Adris
Ljubljana share indices end week up, Telekom Slovenije leads gainers
Dec 31, 2007 13:56 EEST
ZAGREB (Croatia), December 31 (SeeNews) – Croatian drug maker Pliva said on Monday it has sold for an undisclosed price its Spanish commercial operations to Spanish pharmaceutical company Biomedica Foscama Industria Chimico-Farmaceutica, completing the divestment of its non-core business.
"This divestment follows Pliva's previously announced intention to streamline European operations and to focus on specific key markets," the company said in a statement.
You can subscribe to our M&A newsletter here
Biomedica will acquire Pliva's three Spanish subsidiaries Pliva Pharma Iberia, Laboratorios Edigen and Uso Racional, as well as the right to use the trademark Pliva in Spain for a transitional period of up to 18 months.
Pliva is a subsidiary of U.S. pharmaceuticals producer Barr. Pliva’s shares did not trade on the Zagreb bourse on Monday. They closed at 850 kuna ($171/116 euro) on Friday, up 1.8%.
In October, Pliva sold its non-core veterinary subsidiary Veterina through an initial public offering. It also sold this autumn its Italian non-core business to Italian sector company Biomedica.
(1 euro=7.3312 Croatian kuna)
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options